QLT completes sale of punctal plug technology to Mati Therapeutics

Article

QLT entered into an agreement with Mati in December and closed the deal in April.

Vancouver, British Columbia-QLT Inc. has completed the sale of the Company's punctal plug drug delivery system (PPDS) technology to Mati Therapeutics Inc., a development company founded by Robert Butchofsky, QLT's former president and chief executive officer.

In December 2012, QLT entered into an exclusive agreement with Mati under which QLT granted Mati a 90-day option to acquire assets related to QLT's PPDS technology in exchange for $500,000. On April 3, following Mati's exercise of the option, QLT and Mati entered into an asset purchase agreement and completed the sale of PPDS technology to Mati.

Under the terms of the asset purchase agreement, QLT received an additional payment of $750,000 at closing and is eligible to receive potential payments upon the satisfaction of certain product development and commercialization milestones that could reach $19.5 million-or exceed that amount if more than two products are commercialized-a low single-digit royalty on worldwide net sales of all products using or developed from the PPDS Technology, and a fee on payments received by Mati in respect of the PPDS Technology other than net sales.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
© 2025 MJH Life Sciences

All rights reserved.